Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 12/20 | 0.67 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601034 | 0.95 | SCD (0.65) | SCDDCTPP1CYP2C9CYP2C19HTR2B | |
| SCHEMBL1601883 | 0.94 | SCD (0.59) | SCDDCTPP1WNT3A | |
| SCHEMBL1599653 | 0.92 | SCD (0.57) | SCDDCTPP1CYP2C9CYP2C19HTR2B | |
| SCHEMBL1600545 | 0.89 | SCD (0.57) | SCDDCTPP1WNT3A | |
| SCHEMBL1599697 | 0.88 | SCD (0.75) | SCDDCTPP1CYP2C9CYP2C19HTR2B | |
| SCHEMBL1601631 | 0.86 | SCD (0.63) | SCDWNT3ALMNA | |
| SCHEMBL1599942 | 0.86 | SCD (0.65) | SCDDCTPP1CYP2C9CYP2C19HTR2B | |
| SCHEMBL1601058 | 0.86 | SCD (0.65) | SCDWNT3ALMNA | |
| SCHEMBL1600566 | 0.82 | SCD (0.63) | SCDDCTPP1CYP2C9CYP2C19HTR2B | |
| SCHEMBL1096003 | 0.82 | SCD (0.67) | SCDDCTPP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-7763618-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2010-07-27 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500716-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | claimed |
| CN-1829690-A | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20130079354-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-8383628-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | disclosed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | disclosed |
| CN-1829690-A | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079354-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | PRMT9, SNRPD3, PRDX5 | SCD 4/4885DCTPP1 2402/4885CYP2C9 387/4885 |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | PRMT9, SNRPD3, PRDX5 | SCD 4/4885DCTPP1 2402/4885CYP2C9 387/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | SCD 1186/4885DCTPP1 4175/4885CYP2C9 4867/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | SCD 1/4885DCTPP1 3458/4885CYP2C9 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.